Oragenics, Inc. (OGEN) AMEX
0.63
-0.02480005(-3.82%)
Currency In USD
- General
- Statistics
- Historical Data
- Profile
- Financials
0.63
-0.02480005(-3.82%)
Currency In USD
| Previous Close | 0.65 |
| Open | 0.65 |
| Day High | 0.68 |
| Day Low | 0.63 |
| 52-Week High | 9.6 |
| 52-Week Low | 0.61 |
| Volume | 91,604 |
| Average Volume | 547,288 |
| Market Cap | 2.71M |
| PE | -0.14 |
| EPS | -4.56 |
| Moving Average 50 Days | 0.81 |
| Moving Average 200 Days | 1.33 |
| Change | -0.02 |
ORAGENICS EXPLORES EXPANSION OF CNS PLATFORM PURSUING ACQUISTION OF ASSETS IN BRAIN HEALTH, RECOVERY, AND NEUROPROTECTION
GlobeNewswire Inc.
Mar 11, 2026 12:30 PM GMT
SARASOTA, Fla., March 11, 2026 (GLOBE NEWSWIRE) -- Oragenics, Inc. (NYSE American: OGEN), a clinical-stage biotechnology company pioneering brain-targeted therapeutics through proprietary intranasal delivery technology, today announced that it is ex
Oragenics Receives HREC Approval for Phase IIa Clinical Trial of ONP-002 as a Treatment for Concussion and Mild Traumatic Brain Injury in Australia
GlobeNewswire Inc.
Mar 10, 2026 12:30 PM GMT
All required regulatory approvals secured for trial site onboarding and patient enrollment at three Australian sitesPotential first and only pharmacological treatment for the most prominent neurological condition without an FDA-approved therapeutic S
Oragenics Targets Projected $9 Billion Market by Advancing First and Only Clinical-Stage Concussion and Mild Traumatic Brain Injury Therapy
GlobeNewswire Inc.
Feb 09, 2026 1:30 PM GMT
Outlines clinical and growth catalysts for ONP-002 in concussion and mild traumatic brain injury (mTBI) Fully prepared to initiate near-term clinical site onboarding and first patient dosing in Australia Sarasota, Fla., Feb. 09, 2026 (GLOBE NEWSWI